Research programme: neuropeptide Y analogues - Peptech/CRCAlternative Names: Neuropeptide Y analogues research programme - Peptech/CRC; PTL 041120
Latest Information Update: 17 Jul 2001
At a glance
- Originator CRC for Biopharmaceutical Research; Peptech
- Mechanism of Action Neuropeptide Y receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rhinitis
Most Recent Events
- 17 Jul 2001 Discontinued-Preclinical for Rhinitis in Australia (Intranasal)
- 26 Nov 1998 Peptech seeks development partner for neuropeptide Y analogue
- 10 Feb 1998 New profile